成人抗B因子相关肾小球疾病谱系研究
本研究回顾性分析了法国参考中心2017年10月至2020年6月系统性检测抗B因子(抗FB)IgG抗体且同期肾活检证实肾病的71例成人患者,发现抗FB抗体与感染相关性肾小球肾炎(IR-GN)强烈相关,占65%,且抗FB滴度在IR-GN中更高,抗体常随感染控制而消失。
要点
- 成人抗FB抗体阳性者中65%诊断为感染相关性肾小球肾炎。
- 抗FB滴度在IR-GN患者中显著高于其他诊断。
- 抗FB抗体常随感染控制而转阴,持续阳性提示感染未控制。
核心结论
- 成人抗FB抗体检测与感染相关性肾小球肾炎强烈相关,提示替代途径失调的重要机制。
研究设计与样本
- 回顾性病例系列,纳入2017年10月至2020年6月法国补体异常参考中心系统检测抗FB IgG阳性且同期肾活检证实肾病的71例成人患者。
主要发现
- 71例中36例(51%)同时检测到抗FB和抗C3b自身抗体。
- 患者纯化IgG在体外增强替代途径活性,抗FB滴度与C3bB前转化酶形成相关(R2=0.40,P<0.001),抗C3b滴度与C3bBb转化酶稳定相关(R2=0.46,P<0.001)。
- 最常见诊断为感染相关性肾小球肾炎(46/71,65%),其抗FB滴度中位数791(IQR 287-2000)AU/mL,高于其他诊断的326(IQR 173-790)AU/mL,Hodges-Lehmann差354 AU/mL(95%CI 58-1020),P=0.01。
- 抗C3b滴度在IR-GN与其他诊断间无差异。
- 36例复测者中21例(58%)抗FB抗体转阴;10例持续检测超过3个月者中8例(80%)感染未控制。
临床怎么用
- 对补体介导肾病患者应筛查抗FB抗体,阳性可能提示潜在感染并指导治疗决策。
局限性
- 回顾性设计,且参考中心招募导致替代途径异常病例富集。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RATIONALE & OBJECTIVE: Autoantibodies targeting complement factor B (anti-FB) are among the most recently described alternative pathway anomalies. Although they have been strongly associated with post-infectious glomerulonephritis in children, the clinical phenotypes associated with such antibodies, along with their effects on the alternative pathway in adults, remain elusive and require further characterization, which was the goal of this study. STUDY DESIGN: Retrospective case series. SETTING & PARTICIPANTS: Patients for whom anti-FB immunoglobulin G (IgG) was systematically detected by the French reference center for complement abnormalities between October 2017 and June 2020 and who underwent concurrent kidney biopsy confirming kidney disease were included as cases. FINDINGS: Seventy-one patients tested positive for anti-FB antibodies using ELISA and single-bead antigen assays in the setting of newly diagnosed biopsy-proven kidney disease. Detection of both anti-FB and anti-C3b autoantibodies occurred for 36 of 71 patients (51%). In vitro, total purified IgG from these patients enhanced alternative pathway activity, with anti-FB titers being correlated with C3bB proconvertase formation (R2 = 0.40, P < 0.001) and anti-C3b titers being correlated with C3bBb convertase stabilization (R2 = 0.46, P < 0.001), suggesting distinct and potentially synergistic functional effects. Clinically, the most frequent diagnosis associated with anti-FB detection was infection-related glomerulonephritis (IR-GN) (46 of 71, 65%), with higher anti-FB titers in patients with IR-GN compared with other diagnoses (median, 791 [IQR, 287-2,000] vs 326 [IQR, 173-790] AU/mL; Hodges-Lehmann difference, 354 AU/mL [95% CI, 58-1020]; P = 0.01). No difference was detected in anti-C3b titers between IR-GN and other diagnoses. Anti-FB antibodies became undetectable in 21 of 36 retested patients (58%); among the 10 patients with persistent detection beyond 3 months, 8 (80%) had uncontrolled infection. After a median follow-up period of 12.5 (IQR, 5-24) months, 18 of 67 patients (27%) experienced a major adverse kidney event (kidney failure or a sustained ≥50 decline in estimated glomerular filtration rate below the baseline value). LIMITATIONS: Retrospective design, the series was enriched in alternative pathway anomalies due to reference center recruitment. CONCLUSIONS: Detection of anti-FB antibodies is strongly associated with infection-related glomerulonephritis in adult patients, highlighting an important mechanism of alternative pathway deregulation in such diseases. PLAIN-LANGUAGE SUMMARY: Antibodies targeting factor B, a key protein of the complement cascade, have been shown to activate the complement system and promote kidney inflammation. However, the clinical characteristics and outcomes of patients with such autoantibodies remain largely understudied, particularly in adults. This study systematically screened over 700 adults referred for complement investigation and identified 71 patients with anti-factor B antibodies and concurrent biopsy-proven kidney disease. These antibodies were predominantly associated with infection-related glomerulonephritis, activated the alternative complement pathway, and tended to disappear once the underlying infection was controlled. These findings highlight the importance of screening for anti-factor B antibodies in patients with complement-mediated kidney disease, as their detection may prompt the search for an underlying infection and guide therapeutic decisions.
引用
- Brousse R, Roquigny J, El Sissy C, et al. Spectrum of Anti-Factor B-Associated Glomerular Diseases in Adults. Am J Kidney Dis. 2026. PMID: 42575336. doi:10.1053/j.ajkd.2026.06.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。